MEDI1814 / Eli Lilly, AstraZeneca - LARVOL DELTA

AstraZeneca exits neuroscience R&D to focus on obesity and immunology (Chosun Biz) - "The British global pharmaceutical company AstraZeneca (AZ) announced its strategy to withdraw from research and development (R&D) for treatments in the neuroscience field, such as Alzheimer’s disease, and focus more on obesity and immunology....Recently, AZ halted the development of ‘MEDI1814’, an amyloid beta (Aβ) antibody candidate for early Alzheimer’s disease patients, and ‘MEDI0618’, an antibody candidate for migraine treatment....AZ stated it is developing the oral obesity treatment candidate ‘AZD5004’ as a monotherapy while also considering combination therapies with existing low-molecular-weight compounds."

Discontinued • Alzheimer's Disease • Immunology • Migraine • Obesity

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients. (PubMed, Alzheimers Dement) - "MEDI1814 offers a differentiated approach to impacting Aβ in AD via selective reduction of free Aβ42."

Journal • Alzheimer's Disease • CNS Disorders • Aβ42

[VIRTUAL] MEDI1814, A BETA-AMYLOID 42-SPECIFIC ANTIBODY, LOWERED NEUROFILAMENT LIGHT PLASMA LEVELS IN PATIENTS WITH MILD-MODERATE ALZHEIMER’S DISEASE (CTAD 2020) - "MEDI1814, which shows dose-dependent suppression of CSF free Aβ42, reduced NfL levels in plasma. A similar trend of reduction of NfL levels in CSF was observed. This is the first observation of NfL lowering from baseline by an amyloid targeting agent."

Clinical • Alzheimer's Disease • CNS Disorders • CSF Aβ42 • CSF NfL • Plasma NfL

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease (clinicaltrials.gov) - P1; N=121; Recruiting; Sponsor: AstraZeneca; N=242 -> 121 ; Trial primary completion date: Oct 2016 ->Jan 2017

Enrollment change • Trial primary completion date • Alzheimer's Disease • Biosimilar

[VIRTUAL] MEDI1814, A BETA-AMYLOID 42-SPECIFIC ANTIBODY, LOWERED NEUROFILAMENT LIGHT CSF AND PLASMA LEVELS IN PATIENTS WITH MILD-MODERATE ALZHEIMER’S DISEASE (AAT-ADPD 2020) - "Conclusions MEDI1814, which shows dose-dependent suppression of CSF free Aβ42, also reduces NfL levels in CSF and plasma. These preliminary observations in a small sample would benefit from confirmation in further clinical studies."

Clinical • CSF Aβ42 • Plasma NfL